Legislation
European
European Patent Convention
Protocol on interpretation of art. 69
Act revising the Convention on the Grant of European Patents
US
US Code Title 35 Patents (US Patents Act)
Cases
Celltech
Celltech Chiroscience Ltd. v
Medimmune Inc.
[2003] EWCA Civ 1008 (17 July 2003)
Celltech Chiroscience Ltd. v
Medimmune Inc
[2002] EWHC 2167 (Patents) (28 Oct 2002)
Celltech R & D Ltd. v Medimmune Inc
[2004] EWHC 1124 (Patents) (19 May 2004)
Celltech R & D Ltd v Medimmune
Inc
[2004] EWHC 1522 (Pat) (18 June 2004)
Other UK Cases
Merck & Co Inc v Generics (UK)
Ltd.
[2003] EWHC 2842 (Patent) BAILII
Wheatley and another v Drillsafe Ltd
and others
[2000] EWCA Civ 209 (5 July 2000)
Improver Corporation v Remington Consumer Products Limited
[1990] FSR 181
US
Festo Corp. v Shoketsi KKK, and
others
535 U.S. 722 (2002)
Graver Tank & Mfg. Co. v. Linde Air
Products Co.,
339 U.S. 605 (1950
Australia
General Clutch Corporation v Sbriggs
Pty Ltd
[1997] 499 FCA (6 June 1997)
Article
Katherine E. White, FESTO: A Case
Contravening the
Convergence of Doctrine of Equivalents Jurisprudence in Germany, The
United Kingdom, and the United States,
8 Mich Telecomm. Tech L. Rev. 1 (2002),
1 March
2004
Last
Updated 15 Nov 2005
It will be recalled that a patent is a monopoly granted by the state in exchange for disclosing an invention to the public. The document that discloses the invention and delineates the monopoly is called "the specification". S.14 (2) of the Patents Act 1977 requires the to be performed by a person skilled in the art. It also prescribes at least one claim that must be supported by the description which defines the matter for which protection is sought.
Construction of Claims
The matter for which protection is sought is defined in accordance with s.125 of the Act. S.125 (1) requires it to interpreted by reference to the description and any drawings in the specification. Sub-section (3) incorporates by reference the Protocol on Interpretation of art 69 EPC which presently reads:
"Article 69 should not be interpreted in the sense that the extent of the protection conferred by a European patent is to be understood as that defined by the strict, literal meaning of the wording used in the claims, the description and drawings being employed only for the purpose of resolving an ambiguity found in the claims. Neither should it be interpreted in the sense that the claims serve only as a guideline and that the actual protection conferred may extend to what, from a consideration of the description and drawings by a person skilled in the art, the patentee has contemplated. On the contrary, it is to be interpreted as defining a position between these extremes which combines a fair protection for the patentee with a reasonable degree of certainty for third parties".
The important point to note is that the monopoly granted by a patent is bounded by the language of its claims. An extended meaning may be given to such language if that is how it would be understood by the person who would perform the patent. But it is not possible to depart from the language as the Protocol currently stands (see Merck & Co Inc v Generics (UK) Ltd. [2003] EWHC 2842 (Patent) BAILII).
Applying the Protocols
The Court of Appeal considered the application of the Protocol on Interpretation in Wheatley v Drillsafe Ltd [2000] EWCA Civ 209 (5 July 2000) [2001] RPC 133 at paragraph [19]:
"The Protocol outlaws what can be termed strict literal and also liberal interpretation using the claims as a guideline. The correct approach is to achieve a position between those extremes 'which combines a fair protection for the patentee with a reasonable degree of certainty for third parties.' ”
He explained that although a strict literal interpretation using the drawings and specification gives to third parties the most certainty it is seen as unfair to patentees, which is why it is outlawed by the Protocol. So far as a patentee is concerned, it is important that a claim should be interpreted in accordance with his intention. A claim interpreted on the one hand too liberally can render the patent invalid and on the other too literally can allow third parties to avoid the monopoly. The object of interpretation is to ascertain the intention of the patentee.
The Improver Questions
To ascertain such intention, Hoffmann J (as he then was) suggested the following test in Improver Corporation v Remington Consumer Products Limited [1990] FSR 181:
”(1)
Does the variant have a material effect upon the way the invention works? If
yes, the variant is outside the claim. If no-
(2) Would this (i.e. that the variant had no material effect) have been
obvious at the date of the publication of the patent to a reader skilled in
the art. If no, the variant is outside the claim. If yes -
(3) Would the reader skilled in the art nevertheless have understood from
the language of the claim that the patentee intended that strict compliance
with the primary meaning was an essential requirement of the invention. If
yes, the variant is outside the claim.
On the other hand, a negative answer to the last question would lead to the
conclusion that the patentee was intending the word or phrase to have not a
literal but a figurative meaning (the figure being a form of synecdoche or
metonymy) denoting a class of things which included the variant and the
literal meaning, the latter meaning, the latter being perhaps the most
perfect, best-known or striking example of the class.”
The first
2 questions involve considerations of fact. The last is a question of
construction. Aldous LJ explained at paragraph [25] of Wheatley that the
first question envisages that the claim has an ambit wider than the literal
meaning of the words so as to give fair protection for the patentee but that
is subject to the safeguards contained in it when considered with the
second. The third question also provides a fair result for the patentee in
that it avoids an unintended meaning while requiring attention to the
purpose of the words to give fair protection for third parties.
Contrast with the Doctrine of Equivalents
In the USA, a different rule of construction applies. In circumstances where all aids to interpretation have been exhausted and the scope of the claims has been enlarged as far as words can be stretched the courts may on proper occasions make them cover more than their meaning can bear (per Judge Learned Hand in Royal Typewriter v Remington (1948) 168 f. 2d. 691; 77 USPQ 517 (2d Cir.). This rule is balanced by a countervailing doctrine known as "file wrapper estoppel" which essentially means that a patentee may not go back on anything he has said or represented to the US Patent and Trademark Office when applying for a patent. The doctrine of equivalents and file wrapper estoppel have recently been reviewed by the US Supreme Court in Festo Corp. v Shoketsi KKK, and others 535 U.S. 722 (2002). A case that illustrates the differences between the doctrine of equivalents and the Protocol is Celltech Chiroscience Ltd. v Medimmune Inc. [2003] EWCA Civ 1008, [2002] EWHC 2167 (Patents).
Revised Protocol
In Celltech, the trial judge remarked that prosecution history
estoppel along with the doctrine of equivalents had become an elaborate
doctrine with many facets which arise in most patent litigation in the USA.
He observed "Those who suggest similar doctrines for Europe would do well to
bear this in mind - and that the prosecution file may be in any of three
languages." In fact, the doctrine of equivalents may well come to Europe
because the Munich diplomatic conference voted for the following article to
be added to the Protocol:
"For the purpose of determining the extent of protection conferred by a European patent, due account shall be taken of any element which is equivalent to an element specified in the claims."
This article will of, course, be incorporated by reference automatically into English law by s.125 of the Patents Act 1977.
Case Notes
Meaning of "comprising"
John Lambert General Clutch Corporation v Sbriggs Pty Ltd
Numerical Limitations
John Lambert TH Goldschmidt AG and another v. EOC Belgium NV and Others
US Doctrine of Equivalents and File Wrapper Estoppel
John Lambert Celltech Chiroscience Ltd. v Medimmune Inc.
Improver Questions
John Lambert Buchanan v Alba Diagnostics Ltd.
John Lambert Amersham Pharmacia V Amivcon
John Lambert American Home Products Corporation v Novartis Pharmaceuticals UK Ltd.
John Lambert: Horne Engineering Co. Ltd. v Reliance Water Controls Ltd

Important